Toronto, Ontario (April 2, 2021) Thrombosis Canada acknowledges the recommendation of the National Advisory Committee on Immunization (NACI) to suspend the administration of the AstraZeneca SARS-CoV-2 vaccine in patients under 55 years of age. [NACI Statement Link]
Thrombosis Canada, alongside NACI and other healthcare organizations in Canada, is closely monitoring emerging evidence on the safety of the AstraZeneca vaccine and will provide timely updates to healthcare professionals and the public to enable informed decisions about the administration of this vaccine.
In the meantime, Thrombosis Canada continues to strongly recommend that all eligible adults receive the AstraZeneca vaccine, including people with a prior blood clot, those with a blood clotting tendency (e.g., factor V Leiden mutation), and people who are receiving blood thinners as the benefits of receiving the vaccine far outweigh the risks.
For more information on Thrombosis and COVID-19 for patients and families visit here: [LINK]
For more information on Thrombosis and COVID-19 for healthcare professionals visit here: [LINK]
Disclaimer: Please note that the recommendations contained herein must be viewed as general guidelines based on current knowledge. Their application must be adapted to individual patients. Thrombosis Canada assumes no responsibility or liability arising from any error or omission or from the use of any information contained herein. You must not rely on the information in this document as an alternative to medical advice from your doctor or other professional healthcare provider.
PDF of the statement is here: DOWNLOAD